About this trial
In neuroinflammatory diseases of the central nervous system (CNS) such as multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD) and anti-MOG antibody-associated disorders (MOGAD), neuronal degeneration is the consequence of inflammatory and demyelinating lesions in the brain, optic nerve and spinal cord. Both white and grey matter are systematically affected. Lesions of the perivascular spaces containing cerebrospinal fluid (CSF) and meningeal inflammation seem to play an important role in the pathophysiology of these neuroinflammatory diseases. Currently, the interrelation of all these aspects is not clearly established in the pathophysiology of these diseases. In order to better understand the mechanisms that lead to and underlie the clinical disability of patients with these diseases, we need in vivo study models that allow the in-depth study of the neurodegenerative process and the identification of its causes. In this perspective, we make the hypothesis that the visual pathways model is very relevant to measure neuro-axonal loss and to explore the different mechanisms involved in neurodegeneration during MS and other CNS demyelinating diseases. Researchers have at their disposal many tools that allow them to analyse and quantify the neurodegenerative process in a reproducible and very precise manner from a structural and functional point of view, while taking into account possible vascular involvement (MRI, optical coherence tomography - angiography, etc…).
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
- Male or female
Aged between 18 and 65 years
Presenting a clinical picture of optic neuritis for less than 4 weeks, confirmed by neuro-ophthalmological assessment
Patient having given written consent to participate in the study
Disqualifiers
- history of optic neuritis on the same side as the recent episode for which the patient is being treated
history of retinal pathology (retinal detachment, glaucoma, retinopathies, retinal surgery)
diabetes
chronic alcohol intoxication
Trial population
Patients presenting an episode of acute optic neuritis with the objective of better understanding the pathophysiology of CNS inflammatory diseases and identifying prognostic biomarkers in imaging
Trial design
Cohort
Prospective
Treatments tested in this trial
Clinical examen
Other interventionMRI sequences for research, pupillometry, OCT-angiography, evaluation of visual cognition
Treatment groups
Trial outcomes
Primary outcomes
Presence of enhancement of the optic nerve sheath on the axial T1 dixon MRI sequence post gadolinium at the acute phase of optic neuritis.
Low contrast monocular visual acuity (2.5%, LogMAR unit) at distance from acute optic neuritis
Secondary outcomes
Presence of enhancement of the optic nerve sheath on the axial T1 dixon MRI sequence post gadolinium. Macular GCIPL atrophy will be assessed by the variation of mGCIPL volume between inclusion and the maximal follow-up.
Optic nerve lesion length on 3D-DIR sequence. Alteration of retinal microvascularisation between inclusion and the maximal follow-up.
Acute alteration of retinal microvascularisation is assessed by the difference of retinal vascular density between inclusion (V0) and one month later (V1).
Low contrast monocular visual acuity (2.5%, LogMAR unit) measured at 12 months (V5)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.